Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 142 of 6351
-
New drug combo aims to outperform standard therapy for advanced breast cancer
Disease control OngoingThis Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal grow…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Hope for aggressive lymphoma: targeted drug added to chemo in major trial
Disease control OngoingPhase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germ…
Phase 3 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a Four-Drug cocktail erase traces of Hard-to-Treat leukemia?
Disease control OngoingCLL2-BZAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.
Phase 2 • Sponsor: German CLL Study Group • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New combo aims to outsmart tough lung cancer
Disease control CompletedThis is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mu…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a simple health chat slash heart disease and cancer risk?
Prevention Recruiting nowThe County Council of Region Skåne, Sweden, has recently initiated Targeted Health Dialogues in primary care. The prevention program includes health dialogues provided by specially trained personnel, collection of clinical and laboratory data as well as questionnaire data on, e.g…
Sponsor: Region Skane • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Mesothelioma—Can they deliver?
Cure OngoingThis study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an M…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
New drug duo aims to outperform standard lung cancer treatment
Disease control OngoingThe purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally a…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a personal trainer cut heart attack deaths?
Disease control By invitation onlyMyocardial infarction (MI) remains the main cause of death in Europe with about 2 million deaths annually. According to WHO, 30 % of deaths caused by MI could be prevented if the populations adhere to official guidelines for physical activity. However, secondary prevention trials…
Sponsor: Norwegian University of Science and Technology • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Immune cell therapy takes on rare blistering skin disease
Disease control Recruiting nowA phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Phase 1/2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take aim at hard-to-treat blood cancers in kids
Disease control OngoingPatients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR…
Phase 1/2 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Massive trial tests azithromycin to prevent stillbirths and infant deaths in west africa
Prevention OngoingThe double blind randomized controlled trial will assess the efficacy of oral azithromycin administered to pregnant women and/or infants during routine care in preventing stillbirths and mortality through 6-12 months of age in Mali, West Africa, where rates of infant and under fi…
Phase 4 • Sponsor: University of Maryland, Baltimore • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
Promising combo targets genetic weakness in advanced prostate cancer
Disease control OngoingThe purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Se…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Stem cell transplant shows promise for scleroderma patients
Disease control CompletedHSCT has been implemented in (inter)national treatment guidelines for diffuse cutaneous systemic sclerosis (dcSSc) and is offered in clinical care and reimbursed by national health insurance in several European countries. However, data and specific guidelines on the best timing o…
Phase 4 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New antibody therapy shows promise for Hard-to-Treat myeloma
Disease control OngoingThe purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for hard-to-treat lymphoma: drug duo takes on cancer
Disease control OngoingThe purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
Phase 3 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Immunotherapy combo shows promise in advanced lung cancer trial
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail shows promise for rare blood cancer
Disease control OngoingMyelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the disease progressing to acute myeloid…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Friendly mosquitoes take a bite out of dengue in landmark trial
Prevention CompletedThis is a cluster randomized controlled trial (CRCT) to evaluate the efficacy of Wolbachia-infected A. aegypti mosquito releases in reducing the burden of ARBV infection in Brazil over four years. The intervention will be the release of Wolbachia-infected A. aegypti mosquitoes. S…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jun 27, 2026 08:00 UTC
-
Could a targeted pill keep High-Risk breast cancer at bay?
Disease control OngoingPatients with breast cancer, who have completed first line therapy (e.g., radiotherapy, chemotherapy, surgery), and who have to be identified with having a high risk of recurrence of cancer, will be eligible for the study. This patient group is currently offered a standard of car…
Phase 3 • Sponsor: West German Study Group • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New Needle-Based heart treatment could help children with Drug-Resistant heart disease
Disease control CompletedThe primary purpose of this study was to demonstrate the safety and efficacy of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) in children and assessed its performance and functional outcomes in the follow-up. This is a single-arm, single-center study.
Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC